Our free daily oncology focused e-news service.
(Modern Healthcare) Apr 24, 2018 - A House Republican on Tuesday unveiled a proposal that would require hospitals participating in the 340B drug discount program to disclose how much care they provide to low-income patients. But healthcare stakeholders warn the bill could place unfair reporting burdens on providers in medically vulnerable communities.
read article (free registration required)(TIME/Kaiser Health News) Apr 24, 2018 - Keith Beck, who died of bile duct cancer, agreed to a “rapid autopsy,” a procedure conducted within hours of his death on March 28, 2017, so that scientists could learn as much as possible from the cancer that killed him.
read article(STAT) Apr 25, 2018 - There is a lot of money behind providing cancer care, and cancer treatment centers spend an estimated $173 million on advertising each year.
read article(PharmaTimes [UK]) Apr 25, 2018 - The majority of women at high risk of developing breast cancer decide against prophylactic treatment with tamoxifen, suggest findings of a new study funded by Cancer Research UK and published in Breast Cancer Research and Treatment.
read article(Henry Ford Health System) Apr 24, 2018 - Researchers at Henry Ford Hospital compared the patient population of a major U.S. prostate cancer study with patients found in three U.S. cancer databases, ultimately finding the patients of the study to be inconsistent with the average prostate cancer patient.
read press release(COA) Apr 24, 2018 - “Years of independent studies and investigations have uncovered that the 340B program is out of control in many hospitals and is not functioning to help patients in need,” Ted Okon, executive director, COA.
read press release(Medscape Medical News) Apr 25, 2018 - The Trump administration intends to use the annual update of the Medicare payment rule to rebrand and streamline electronic data reporting requirements, abandoning the much derided "meaningful use" name.
read article (free registration required)(Reuters) Apr 25, 2018 - Takeda Pharmaceutical Co Ltd’s $64 billion bid for London-listed rare disease specialist Shire Plc bolsters its credentials as Japan’s most outward facing drugs firm, a mould-breaking image that has been more than a decade in the making.
read article(BioPharma Dive) Apr 24, 2018 - First-quarter earnings reports have trickled in for the last week and a half, but will really kick into high gear on April 26 when six biotech and pharma heavy hitters all report on the same day.
read article
